These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 7555036)

  • 101. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.
    Bajaj JS; Heuman DM; Wade JB; Gibson DP; Saeian K; Wegelin JA; Hafeezullah M; Bell DE; Sterling RK; Stravitz RT; Fuchs M; Luketic V; Sanyal AJ
    Gastroenterology; 2011 Feb; 140(2):478-487.e1. PubMed ID: 20849805
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis.
    Zeneroli ML; Venturini I; Stefanelli S; Farina F; Miglioli RC; Minelli E; Amedei ER; Ferrieri A; Avallone R; Baraldi M
    Pharmacol Res; 1997 Jun; 35(6):557-60. PubMed ID: 9356209
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Lactulose (cephulac) in portosystemic encephalopathy.
    Kosman ME
    JAMA; 1976 Nov; 236(21):2444-5. PubMed ID: 989871
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver.
    Ali B; Zaidi YA; Alam A; Anjum HS
    J Coll Physicians Surg Pak; 2014 Apr; 24(4):269-73. PubMed ID: 24709242
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Use of rifaximin in gastrointestinal and liver diseases.
    Shayto RH; Abou Mrad R; Sharara AI
    World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.
    Morgan MY; Hawley KE
    Hepatology; 1987; 7(6):1278-84. PubMed ID: 3315932
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.
    Feuerstadt P; Hong SJ; Brandt LJ
    Dig Dis Sci; 2020 Feb; 65(2):632-638. PubMed ID: 31440997
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.
    Mullen KD; Sanyal AJ; Bass NM; Poordad FF; Sheikh MY; Frederick RT; Bortey E; Forbes WP
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1390-7.e2. PubMed ID: 24365449
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience.
    Mantry PS; Mehta A; Graydon R
    Transplant Proc; 2014 Dec; 46(10):3481-6. PubMed ID: 25498076
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Drug therapy: rifaximin.
    Bajaj JS; Riggio O
    Hepatology; 2010 Oct; 52(4):1484-8. PubMed ID: 20814894
    [No Abstract]   [Full Text] [Related]  

  • 111. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
    Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
    Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain.
    Congly SE; Leise MD
    Am J Gastroenterol; 2014 Apr; 109(4):598. PubMed ID: 24698864
    [No Abstract]   [Full Text] [Related]  

  • 113. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
    Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
    World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Hepatic encephalopathy - recent advances in treatment and diagnosis.
    Nardelli S; Gioia S; Faccioli J; Riggio O; Ridola L
    Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):225-235. PubMed ID: 36843291
    [TBL] [Abstract][Full Text] [Related]  

  • 115. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α.
    Orr JG; Currie CJ; Berni E; Goel A; Moriarty KJ; Sinha A; Gordon F; Dethier A; Dillon JF; Clark K; Richardson P; Middleton P; Patel V; Shawcross D; Preedy H; Aspinall RJ; Hudson M
    Liver Int; 2016 Sep; 36(9):1295-303. PubMed ID: 26950766
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
    Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT; Fuchs M; Ridlon JM; Daita K; Monteith P; Noble NA; White MB; Fisher A; Sikaroodi M; Rangwala H; Gillevet PM
    PLoS One; 2013; 8(4):e60042. PubMed ID: 23565181
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Management of hepatic encephalopathy: focus on antibiotic therapy.
    Festi D; Vestito A; Mazzella G; Roda E; Colecchia A
    Digestion; 2006; 73 Suppl 1():94-101. PubMed ID: 16498257
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Liver: the gut is a key target of therapy in hepatic encephalopathy.
    Sawhney R; Jalan R
    Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):7-8. PubMed ID: 25348849
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.
    Garcovich M; Zocco MA; Roccarina D; Ponziani FR; Gasbarrini A
    World J Gastroenterol; 2012 Dec; 18(46):6693-700. PubMed ID: 23239905
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis.
    Elsabaawy MM; Assem M; Badran H; Mahmoud A; Elsabaawy D; Ragab A
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1022-1028. PubMed ID: 38973543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.